Public-domain · open source
OpenJurist
← 921 F.3d 1372 - Neptune Generics, LLC v. Eli Lilly & Co.

Neptune Generics, LLC v. Eli Lilly & Co.’s Empirical Analysis

921 F.3d 1372 · 2019

Citation profile

1
cited by 1 later decisions
August 2019
most recently cited

1 federal appellate ·

Relationships

Applies 28 U.S.C. § 1295 · 35 U.S.C. § 102 · 35 U.S.C. § 311

Relies on KSR International Co. v. Teleflex Inc. · WBIP, LLC v. Kohler Co. · Belden Inc. v. Berk-Tek LLC · Intelligent Bio-Systems, Inc. v. Illumina Cambridge Ltd. · Arctic Cat Inc. v. Bombardier Recreational Products Inc.

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 1 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

  1. “12. An improved method for administering pemetrexed disodium to a patient in need of chemotherapeutic treatment, wherein the improvement comprises: a) administration of between about 350 µg and about 1000 µg of folic acid prior to the first administration of pemetrexed disodium; b) administration of about 500 µg to about 1500 µg of vitamin B12, prior to the first administration of pemetrexed disodium; and c) administration of pemetrexed disodium.”
    1 later decision quote this exact passage · from the majority
  2. “Role of Folic Acid in Modulating the Toxicity and Efficacy of the Multitargeted Antifolate, LY231514,”
    1 later decision quote this exact passage · from the majority

How this case has been treated — in progress

Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.